Health
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...
Beauty Farm Announces 2023 Annual Results
Revenue and Net Profit Reached Record High Acquisition of Naturade, China's Second-Largest Market Share Brand HONG KONG, March 26, 2024 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services provide...
ANICAV Promotes Sustainability and Wellbeing with Veganism with Legumes from Europe project
SYDNEY, March 26, 2024 /PRNewswire/ -- The Legumes from Europe project, promoted by ANICAV, aims to boost consumption inAustralia of high-quality canned legumes from the "Old Continent". Among the many objectives, improving environmental sustainability and personal well-being and protecting the p...
Minesto presents today at Naventus Renewables Summit, Stockholm
GOTHENBURG, Sweden, March 26, 2024 /PRNewswire/ -- Minesto's CEO Dr Martin Edlund presents today at Naventus Renewables Summit held in Stockholm, 26 March 2024. The event is livestreamed, and Minesto will be presenting at 14.40 CET: Naventus & Partners Renewables Summit 2024 For additional ...
Cicada Innovations launches HealthTech Hub in Western Sydney's "hidden innovation ecosystem"
SYDNEY, March 26, 2024 /PRNewswire/ -- Australia's flagship deep tech incubator
Cicada Innovations
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...
Scivita Medical Expands Collaboration with Boston Scientific
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical
Technology Co., Ltd. ("Scivita Medical") and Boston
Scientific Corporation (NYSE: BSX), a leading global medical technology
company, joined hands again to sign an expanded strategic cooperation
arrangement.
BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167
SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...
GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions Through Its Unified Virtual Care Platform
GenieMD offers a comprehensive virtual care platform, integrating telehealth, remote patient monitoring, chronic care management, and AI-driven insights to impact the treatment and management of chronic diseases. SAN ANTONIO, March 25, 2024 /PRNewswire/ -- Frost & Sullivan recently researched th...
Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member
WOBURN, Mass., March 25, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the appointment ofMatt Schmidt as chief executive officer and board of directors member, effectiveMarch 25. Since joining Sirtex in 2023, Schmidt...
CGTN: China advances battle against tuberculosis
BEIJING, March 25, 2024 /PRNewswire/ -- World Tuberculosis (TB) Day, which falls onMarch 24 every year, is designed to build public awareness that TB today remains a global public health problem that seriously endangers people's health. According to the World Health Organization's (WHO) Global T...
ANNOUNCEMENT OF 2023 ANNUAL RESULTS OF TONG REN TANG TECHNOLOGIES
BEIJING, March 25, 2024 /PRNewswire/ -- Tong Ren Tang Technologies Co. Ltd. (" Tong Ren Tang Technologies" or the "Group", 1666.HK) is pleased to announce the audited consolidated results of the Group for the year ended31 December 2023. In 2023, the Group's revenue amounted to RMB6.77 billion, rep...
Medipledge, a premium post-laser skincare brand, just launched in Australia
SYDNEY, March 25, 2024 /PRNewswire/ -- On March 24th, 2024, Medipledge, a premium skincare brand developed by experts in beauty and dermatology, successfully launched inAustralia. The launch event, held in Australia, featured high-tech elements and included high-end aesthetic therapists, lead...
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today inManila, wi...
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
SINGAPORE, March 25, 2024 /PRNewswire/ -- Juniper Biologics
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...
Veeva Vault EDC Surpasses 1,000 Study Start Milestone
Eight of the top 20 biopharmas standardize on Vault EDC to build a modern
clinical data foundation
SINGAPORE, March 25, 2024 /PRNewswire/ -- Veeva Systems
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
Duyun Maojian tea forest enters spring harvest season in China's Guizhou
DUYUN, China, March 22, 2024 /PRNewswire/ -- Duyun Maojian tea leaves mainly grow in Duyun City, Bouyei-Miao Autonomous Prefecture of Qiannan, southwest China's Guizhou Province. In history, they were used as a tribute to the imperial court and given the name "fish hook tea" since dried tea leaves...
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00